Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

iRadimed Raises FY2025 Adj EPS Guidance from $1.76-$1.86 to $1.84-$1.88 vs $1.82 Est; Raises FY2025 Sales Guidance from $80.000M-$82.500M to $82.500M-$83.500M vs $81.091M Est

Author: Benzinga Newsdesk | November 03, 2025 08:35am
iRadimed (NASDAQ:IRMD) raises FY2025 Adj EPS guidance from $1.76-$1.86 to $1.84-$1.88 vs $1.82 analyst estimate. Raises FY2025 sales outlook from $80.000 million-$82.500 million to $82.500 million-$83.500 million vs $81.091 million estimate.

Posted In: IRMD


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist